Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.

By A. Gordon, A. Mason, Neeraja Thirunavukkarasu, G. Perkins, M. Cecconi, Magda Cepkova, D. Pogson, H. D. Aya, A. Anjum, Gregory J. Frazier and 3 more. Journal of the American Medical Association (JAMA), 2016

627 citations recorded by the source corpus.

Subfields: Epidemiology, Nephrology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0a2e8f0595aed35457448e71c5f52e2cd0ccb618

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Claudio Ronco
2. John A. Kellum
3. Sean M. Bagshaw
4. R. Bellomo
5. A. Rhodes
6. Laura Evans
7. M. Cecconi
8. Janice L. Zimmerman

In Nephrology

1. John A. Kellum
2. R. Bellomo
3. Claudio Ronco
4. Sean M. Bagshaw
5. M. Ostermann
6. R. Chang

Citations in the corpus

• Acute kidney injury in sepsis (2017, methodology): “Norepinephrine as Initial Therapy in Septic Shock (VANISH) trial, AKI occurred in about 45% of patients, and AKI requiring RRT developed in 30% of patients [21].”
• Sepsis and septic shock. (2018, background): “96 In a UK multicentre RCT published in 2016, vasopressin did not decrease the number of kidney failure-free days 97 compared with norepinephrine.”
• Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before‐After Study (2017, methodology): “In the VANISH (Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock) trial, the median time to shock reversal was 45 h (interquartile range, 23-75 h).(66) The mean duration of vasopressor dependency in the patients treated with vitamin C in the study by Fowler et al(16) was 86 h.”
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (2017, background): “When comparing albumin to HES, albumin resulted in lower risk of death (OR, 0.73; CrI, 0.56–0.93; moderate-quality evidence) and a trend toward less need for RRT (OR, 0.74; CrI, 0.53–1.04; lowquality evidence) (237).”